Last reviewed · How we verify
amoxicillin or moxifloxacin + rifampicin — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
amoxicillin or moxifloxacin + rifampicin (amoxicillin or moxifloxacin + rifampicin) — Centre Hospitalier Universitaire de Nice.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| amoxicillin or moxifloxacin + rifampicin TARGET | amoxicillin or moxifloxacin + rifampicin | Centre Hospitalier Universitaire de Nice | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- amoxicillin or moxifloxacin + rifampicin CI watch — RSS
- amoxicillin or moxifloxacin + rifampicin CI watch — Atom
- amoxicillin or moxifloxacin + rifampicin CI watch — JSON
- amoxicillin or moxifloxacin + rifampicin alone — RSS
Cite this brief
Drug Landscape (2026). amoxicillin or moxifloxacin + rifampicin — Competitive Intelligence Brief. https://druglandscape.com/ci/amoxicillin-or-moxifloxacin-rifampicin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab